Physician profile
David Alan Schwartz
NPI 1932187580
$1,104.15
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $125 · 2022: $101 · 2023: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $167.08 | 2019-2020 | |
| Lilly USA, LLC | $149.67 | 2019-2023 | Mounjaro |
| Pfizer INC. | $105.78 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $84.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $73.41 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $71.27 | 2019-2020 | |
| Amgen INC. | $62.87 | 2019 | |
| Novo Nordisk INC | $62.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.80 | 2019 | |
| Arbor Pharmaceuticals, INC. | $37.42 | 2019 | |
| Glaxosmithkline, LLC. | $34.79 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $33.21 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $31.13 | 2019 | |
| Horizon Therapeutics Plc | $30.95 | 2019 | |
| Abbvie INC. | $29.85 | 2023 | Qulipta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.94 | 2019 | |
| Merck Sharp & Dohme LLC | $23.62 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $14.17 | 2019 | |
| Allergan, INC. | $13.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.